"Biosimilars: U.S. Payer Perspectives," a report by FirstWord that provides details on the U.S. biologics market and gives insights from 12 United States payers from a variety of different organizations, projects spending on biologics will reach $100 billion in the U.S. over the next few years.
“Biosimilars are seen as a potential safety valve that can relieve some of the pressure on a healthcare system that is creaking under the weight of declining resources, increasing demands and expensive new product launches,” the report said. “Caught in the middle of this are the payers, an important stakeholder group whose voice and insight is critically important in understanding the opportunities, challenges and critical success factors that companies operating in the U.S. biosimilars market need to know and understand.”
The report provides unique payer insights on some of the vital, market-shaping issues that are leading discussions including pricing, substitution, switching, indication extrapolation, naming, and originator company defensive tactics.
There are many opportunities for biosimilar developers in the U.S. market, but to influence these opportunities and enlarge chances of success, biosimilar developers and originator companies can read the report to understand what payers think and how they will act in response to cheaper biologics becoming available.